AI CDI & utilization review
35 – 40SmarterDx by 5
| Dimension | Navina | SmarterDx | Gap |
|---|---|---|---|
| EHR & deploymentDepth of EHR integration, concurrent versus retrospective review support, reviewer worklist prioritization, and the implementation burden on IT and HIM. | 7 | 9 | -2 |
| Capture accuracyHow reliably the tool finds genuine documentation gaps — diagnosis specificity, HCC recapture, severity and acuity capture — without flooding reviewers with false positives. | 8 | 9 | -1 |
| Traceability & auditabilityWhether every suggested code or query anchors to a verbatim phrase in the record, and whether the audit trail would survive a payer or RAC review. | 8 | 9 | -1 |
| Revenue & denial impactDocumented effect on case mix index, DRG accuracy, denial rates and appeal outcomes, weighted toward externally reported results over vendor claims. | 8 | 9 | -1 |
| Access & transparencyPublished pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle. | 4 | 4 | — |
Navina
- Best for
- Primary care and risk-bearing ambulatory groups that need longitudinal chart synthesis, HCC suspecting and point-of-care evidence linked back to labs and specialist notes.
- Limitation
- Purpose-built for outpatient value-based care and HCC workflows rather than inpatient DRG and acute utilization review.
- Price
- Enterprise and medical-group licensing, sales-led
SmarterDx
- Best for
- Hospitals that want a pre-bill AI pass over finished charts — labs, imaging, vitals, meds and notes — to catch missed revenue and denial risk before the claim goes out.
- Limitation
- Acute-care focused and enterprise-only, so it does not serve ambulatory groups or individual clinicians.
- Price
- Enterprise, sales-led; no published rate
